Top CMO pushes for routine genome screening on NHS
July 4, 2017Manufacturing and Production, Research and Development NHS, genome sequencing
England’s top Chief Medical Officer has called for routine DNA testing to become standard on the NHS in a bid …
Ministers move to clarify drug regulation Post-Brexit
July 4, 2017Manufacturing and Production, Medical Communications EMA, Jeremy Hunt, MHRA, NHS, NICE
Jeremy Hunt, Health Secretary, and Greg Clark, Business Secretary, have made a bold move to suggest that the UK will …
AstraZeneca generates $600 million from just two drug sales
July 3, 2017Manufacturing and Production, Sales and Marketing AstraZeneca, Seloken, Zomig
AstraZeneca is expected to generate almost $600 million from just two drug sales: Zoming, a migraine therapy, and Seloken, a …
Forging a path forward in neurological disorders
July 3, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing neurological disorders
The development of innovative treatments for neurological disorders such as dementia has stagnated over the past decade despite being an …
Big success and even bigger failure for Daiichi Sankyo’s experimental therapy
July 3, 2017Research and Development, Sales and Marketing Daiichi Sankyo, mirogabalin
Daiichi Sankyo has been hit with mixed news this week regarding its experimental therapy mirogabalin. The drug posted trial success …
GSK signs $43 million AI-based drug discovery deal with Exscientia
July 3, 2017Research and Development, Sales and Marketing AstraZeneca, Exscientia, GSK
With AI partnerships becoming increasingly common in the life sciences industry, it has emerged that GSK is to partner up …
New Pfizer EU approval offers first treatment option for leukaemia subtype
July 3, 2017Sales and Marketing AstraZeneca, Besponsa, EU, European Commission
Pfizer has revealed that its drug Besponsa (inotuzumab ozogamicin) has received approval from the European Commission as a monotherapy for …
Free Webinar: How will quality management change by 2025?
July 3, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharmafocus, Webinar, veeva
Following on from the success of our previous free webinar sessions, Pharmafocus is partnering
NICE recommends AstraZeneca lung treatment
July 3, 2017Sales and Marketing AstraZeneca, Daxas, NICE
AstraZeneca’s Daxas (roflumilast) has received recommendation from NICE for the treatment of chronic obstructive pulmonary disease (COPD) it has emerged, …
Pricing Consultant Job Profile and Description
June 30, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GPI
Pricing Consultant Job Profile and Description About Global Pricing Innovations (GPI)
Head of Product Innovation Job Profile and Description
June 30, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GPI
Head of Product Innovation Job Profile and Description About Global Pricing Innovations (GPI)
Development Manager Job Profile and Description
June 30, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GPI
Development Manager Job Profile and DescriptionGPI is a global pricing consultancy launching products, services and offerings that make a measurable …
ABPI reveals 10% increase in HCP payment disclosure
June 30, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Astellas, disclosure, disclosure uk
The headline news from the ABPI’s press conference on Disclosure UK was that healthcare professionals’ (HCPs) disclosure of payments for …
Eli Lilly arthritis drug outperforms Humira and receives NICE backing
June 30, 2017Medical Communications, Research and Development, Sales and Marketing Eli Lilly, NICE, Olumiant, rheumatoid arthritis
Eli Lilly’s rheumatoid arthritis (RA) drug Olumiant (baricitinib) has been deemed cost-effective by NICE and has been recommended to be …
The pharmaceutical research and development challenge
June 30, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing R&D, pharmafile
This report from Kalorama Information was featured in the Spring 2017 edition of Pharmafile. Despite new approaches, new technologies and …
Top Ten most popular articles on Pharmafile.com this week
June 30, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
It’s Friday, and we’ve brought together our weekly digest of the articles which proved most popular with our readers. Mylan …
‘He was born this way’, Shkreli case becomes circus
June 29, 2017Medical Communications Martin Shkreli, Shkreli, Turing Pharmaceutical, turing
Martin Shkreli’s Attorney, Benjamin Brafman, defended his client in a bizarre reference to a pop singer, “As Lady Gaga would …
American Cancer Society and Melanoma Research Alliance join forces to bring down immunotherapy side-effects
June 29, 2017Medical Communications, Research and Development American Cancer Society, Cancer, Melanoma Research Alliance, immunotherapy
The American Cancer Society (ACS) and the Melanoma Research Alliance (MRA) have formed a research partnership to reduce the impact …
Sarepta appoints ex-Allergan President as new CEO
June 29, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sarepta Therapeutics
Sarepta Therapeutics has announced the appointment of ex-Allergan President Doug Ingram as the company’s new CEO – it’s third in …
Regulators get aggressive on matters excessive
June 29, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CMA, Drug pricing, European Commission, Pfizer, aspen
Gustaf Duhs, Partner at Stevens & Bolton, discusses the recent cases of regulators becoming firmer with drug companies over their …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
